The mixture use of Darzalex in mixture with Revlimid, Velcade and Ozurdex demonstrated a better share of stringent full responses amongst transplant eligible, newly recognized sufferers with a number of myeloma.
“The data from the phase 2 GRIFFIN trial underlines the potential of daratumumab when used in combination with VRd and supports Janssen’s decision to start the PERSEUS and CEPHEUS phase 3 studies of daratumumab in combination with VRd for certain frontline multiple myeloma indications,” stated Dr. Jan van de Winkel, chief govt officer of Genmab, the drug’s producer.
The randomized, open label, parallel task trial, which included 223 sufferers with newly recognized a number of myeloma who have been eligible for high-dose chemotherapy and autologous stem cell therapy, met its major endpoint of a better charge of stringent full response in contrast with VRd alone (42.four% vs. 32.zero%).
Secondary endpoints, together with the outcomes of the minimal residual illness evaluation, supported the first endpoint backing the use of Darzalex in mixture with VRd.
Further evaluation of the protection and efficacy information is ongoing and Janssen Biotech, Inc., which licensed Darzalex from Genmab in 2012, has plans to current further information at an upcoming medical summit.
Overall, the protection profile of Darzalex used in mixture with VRd was in keeping with the protection profile for every separate remedy, which has been reported from earlier research.
“This data also builds on the efficacy and safety data for daratumumab as a frontline treatment for transplant eligible multiple myeloma patients as seen in the CASSIOPEIA phase 3 study in which newly diagnosed patients with multiple myeloma who were candidates for (autologous stem cell transplantation) were treated with daratumumab combined with an immune-modulatory drug and a proteasome inhibitor,” van de Winkel added.